GOOD READS

Fitch Rates Boston Scientific's Notes Offering 'BBB-'; Outlook Stable

CHICAGO--(BUSINESS WIRE)--

Fitch Ratings has rated Boston Scientific Corp.'s (BSX) $1.05 billion senior unsecured notes offering 'BBB-'. The net proceeds of the issuance with the recently completed $400 million bank term loan are expected to be used to redeem its $600 million public notes due June 2014 and its $850 million public notes due January 2015. A full list of BSX's ratings follows at the end of this release. The Rating Outlook is Stable.

KEY RATING DRIVERS:

--Fitch expects BSX will operate with relatively stable leverage (total debt/EBITDA) of 2.3x to 2.5x during the next 12 months, despite a challenging operating environment. Nevertheless, current leverage of 2.5x at March 31, 2013 leaves only modest flexibility within the company's 'BBB-' rating category.

--Fitch forecasts that BSX will continue to generate consistently solid free cash flow (FCF), owing to fairly durable margins, relatively dependable revenue and manageable CAPEX requirements. The company is expected to maintain adequate liquidity through revolver availability and access to the capital markets.

--Fitch anticipates that BSX and the industry will continue to face soft procedure volumes in Cardiac Rhythm Management (CRM) and Interventional Cardiology (IC) segments in the near term. However, BSX's remaining businesses (in aggregate) should generate solid single-digit growth.

--Pricing in the CRM and drug-eluting stent segments will likely remain a challenge, although new product introductions and cost control initiatives should help to support margins.

--Fitch believes that the company's litigation profile poses some financial risk, although the risk has been mitigated during the last four years.

FLAT DEBT LEVELS NEEDED FOR STABLE LEVERAGE IN NEAR TERM:

Fitch expects modest top-line and margin headwinds for BSX during the next 12 months. European austerity measures, moderate shifts in treatment paradigms and more aggressive negotiating postures taken by U.S. hospital providers are weighing on the medical device industry. As such, these operating pressures will likely drive BSX to keep debt levels relatively flat, in order to maintain leverage within the 2.3x-2.5x range. Fitch expects growth and profitability to improve thereafter, which will enable the company to reduce leverage without significant reliance on debt reduction.

SOLID CASH FLOW FORECASTED:

Fitch forecasts that BSX will generate $900 million to $1 billion of free cash flow during 2013, compared to approximately $1.03 billion during 2012. Relatively flat sales and efforts to support margins through continued cost controls and new product introductions will not entirely offset the Affordable Care Act's (ACA) 2.3% U.S. sales tax that became effective this year.

CRM AND IC MARKETS TO REMAIN SOFT IN NEAR TERM:

Fitch anticipates that BSX's CRM business will remain modestly challenged during the near term but not as much as in the last two years. BSX's CRM business has declined 7% during the LTM period ended March 31, 2013, primarily because of lingering effects of a negative article published in the Journal of American Medical Association (January 2011) highlighting the practices of U.S. physicians regarding the implanting of implantable cardiac defibrillators, unfavorable foreign exchange movements, and weak pricing. However, new product introductions and strong growth in emerging markets are helping to mitigate the industry factors that are dampening growth.

BSX's IC segment has declined 15% during the LTM period ended March 31, 2013, largely driven by heightened competition in the drug eluting stent market, European austerity measures and pricing. Fitch expects BSX will return this segment to growth in 2014, as it introduces new products. In addition, BSX has improved margins in this segment, as it converted Promus sales (which BSX shares profitability with Abbott Labs) to Promus Element sales, which are roughly twice as profitable for BSX.

STEADY PERFORMANCE IN REMAINING SEGMENTS:

Endosurgery, Neuromodulation, Peripheral Interventions and Electrophysiology are expected, in the aggregate, to deliver solid single-digit growth. The related surgical procedures in these segments are experiencing decent growth, and the devices are not as highly priced as those in the CRM and DES segments. Given the relatively smaller dollars at stake for these segments (relative to CRM and DES), payers do not appear as focused on price. In addition, Fitch expects BSX will continue to launch new products in these respective markets. As such, Fitch believes that segment margins will remain somewhat stable.

LITIGATION AND REGULATORY CONCERNS:

BSX continues to make progress in resolving litigation issues, resulting in an improved litigation risk profile compared to four years ago. However, financial risk related to other litigation remains, and the company will need to plan accordingly for any potential settlements, as it sets its priorities for cash deployment.

The healthcare reform-related 2.3% excise tax on U.S. device sales, which was implemented in January 2013, is expected to pressure margins by approximately one percentage point. However, Fitch believes BSX's focus on cost reduction and the continued development of new value-added, higher margin devices will help to mitigate this risk.

Healthcare reform should also result in moderate volume increases in 2014-2016, when a portion of the uninsured are expected to obtain coverage. Though the Centers for Medicare and Medicaid Services (CMS) has not yet written all of the rules and regulations for the reform law, Fitch does not expect the eventual implementation of healthcare reform to affect BSX's credit rating.

PRIORITIES FOR CASH:

Fitch believes BSX's acquisition strategy will remain targeted, focusing on areas that offer innovation and growth. BSX will likely consider further share repurchases in lieu of debt reduction, assuming its operational profile improves as Fitch forecasts.

Fitch anticipates free cash flow (FCF) will be sufficient to fund targeted acquisitions and share repurchases. As such, Fitch expects BSX will operate with leverage (total debt/EBITDA) ranging between 2.3x-2.5x during 2013. However, at current leverage of 2.5x, the company has only modest financial flexibility to take on additional debt.

ADEQUATE LIQUIDITY:

FCF for the LTM ending March 31, 2013 was $1.03 billion. At the end of the period, BSX had approximately $207 million in cash/short-term investments; full availability on its $2 billion revolver, maturing on April 18, 2017; and full availability on its $350 million 364-day accounts receivable facility. The company had approximately $4.25 billion in debt, with roughly $600 million maturing in 2014, $1.25 billion in 2015, and $600 million in 2016.

RATING SENSITIVITIES:

Positive: Future developments that may, individually or collectively, lead to positive rating action include the following:

--Continued operational improvements, including returning to consistently positive revenue growth and margin stabilization;

--Resulting increases in FCF that are significant and durable;

--Further progress on favorably resolving outstanding litigation issues;

--An operational profile and capital structure that would sustain leverage below 2.2x.

Negative: Future developments that may, individually or collectively, lead to negative rating action include the following:

--Continued declines in revenue and margin pressure;

--Resulting material deterioration in FCF;

--Persistent increase in leverage above 2.8x;

--Leveraging acquisitions without the prospect of timely debt/leverage reduction;

--Significant adverse outcome(s) of litigation issues.

Fitch rates BSX debt as follows:

--IDR at 'BBB-';

--Unsecured bank credit facility at 'BBB-';

--Senior unsecured notes at 'BBB-'.

The Rating Outlook is Stable.

Additional information is available at 'www.fitchratings.com'.

Applicable Criteria and Related Research:

--'Corporate Rating Methodology' (Aug. 8, 2012).

Applicable Criteria and Related Research:

Corporate Rating Methodology: Including Short-Term Ratings and Parent and Subsidiary Linkage

http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=715139

Additional Disclosure

Solicitation Status

http://www.fitchratings.com/gws/en/disclosure/solicitation?pr_id=798980

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE.

Contact:
Fitch Ratings
Primary Analyst
Bob Kirby
Director
+1-312-368-3147
Fitch Ratings, Inc.
70 W. Madison St.
Chicago, IL 60602
or
Secondary Analyst
Megan Neuburger
Senior Director
+1-212-908-0501
or
Committee Chairperson
Mark Sadeghian
Senior Director
+1-312-368-2090
or
Media Relations
Brian Bertsch
+1-212-908-0549
brian.bertsch@fitchratings.com

Quiz: How well do you know India's economy?

Question 1

Which of these products is India the world's largest producer of?

Poll Choice Options
  • Wheat
  • Rice
  • Milk
1
2
3
4
5
6
7
8
9
10

Latest News

  • White House considers former banking lawyer for Fed board - sources

    NEW YORK/WASHINGTON (Reuters) - A former lawyer with the American Bankers Association is being considered by the White House as a possible nominee to the board of the Federal Reserve, according to sources familiar with the efforts The lawyer's name emerged as the White House weighs candidates with community banking backgrounds to fill gaps on the Federal Reserve's powerful but depleted board, the sources said. People familiar with the White House's process said administration officials may …

  • Apple expands buybacks by $30 billion, OKs 7-for-1 stock split

    Apple Inc (AAPL.O) has approved another $30 billion in share buybacks till the end of 2015 and authorized a rarely seen seven-for-one stock split, addressing calls to share more of its cash hoard while broadening the stock's appeal to individual investors. Activist investor Carl Icahn, who had famously called on the iPhone maker to boost its buyback program, tweeted his approval of the move on Wednesday. On Wednesday, Apple reported sales of 43.7 million iPhones in the quarter ended March, …

  • Buffett: moving oil by rail safely major industry concern

    Warren Buffett, chairman of conglomerate Berkshire Hathaway (BRKa.N), said on Wednesday that safety is a major priority for the rail industry, after a recent spate of accidents raised concerns about how to transport oil safely. He added that the delay in the construction of the Keystone pipeline was unlikely to prompt additional purchases of tank cars at Berkshire railroad unit BNSF. Buffett also said, in an interview with CNBC the same day, that he thinks Coca-Cola's (KO.N) equity …

  • Asia markets: Tech sector brightens as Apple jumps 8 percent

    Asian markets could get a lift on Thursday after tech heavyweights Apple and Facebook beat Wall Street expectations, sending their stock up sharply and boosting Nasdaq futures. The Nasdaq futures were up 1 percent and the S&P 500 0.3 percent. Sentiment on the tech sector brightened after Apple (AAPL.O) decided to buy back $30 billion of its shares out to the end of 2015 and authorized a seven-for-one stock split. Apple reported sales of 43.7 million iPhones in the quarter ended March, far …

  • India may cede top rice exporter spot under Southeast Asian price onsl …

    India's rice exports could slide by nearly a quarter this year and knock the country off its perch as top exporter of the grain due to stiff competition from Southeast Asian rivals that have recently slashed prices, Indian industry executives said. A drop in Indian exports could help Thailand trim a record inventory chalked up under a controversial rice-buying scheme. Thailand may also be able to reclaim its status as the world's biggest rice exporter, which it lost to India two years ago. …

IN-DEPTH ANALYSIS & INTERVIEWS

  • This might well be India’s biggest Ponzi scam

    It was just too good to be true. Ashok Khital, 45, displays every symptom of a man who knows he's been conned. …

  • India's star studded football league

    High and mighty including Sachin, Salman & Sun Group buy ISL teams …

  • Leaderspeak with Rajesh Janey

    Rajesh Janey, President - India & SAARC, EMC shares many firsts in his life. …

  • Power Hungry

    Gujarat has power round-the-clock. Most other states do not. Why this will matter in the general elections. …

  • Etcetera

    The most keenly watched contest of the current general election will be the one for the Varanasi parliamentary seat, where the Bharatiya Janata Party's prime ministerial hopeful Narendra Modi squares off ... …

  • Economy vs Democracy

    As the country gets election fever, cash comes out of mattresses and turns into liquor, gifts, and food. But it is not bad for the health of the economy, reports Sarika Malhotra from the trenches. …

  • Bracing for Challenges

    Raghuram Rajan is preparing to deal with concerns that may arise when a new government takes charge. …

MARKET MOVERS

    •  
      Recent Quotes
      Symbol Price Change % ChgChart 
      Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
      You need to enable your browser cookies to view your most recent quotes.
    • Recent Quotes News

      •  
        Sign-in to view quotes in your portfolios.